ImmuPharma : receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP
ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP 12th April 2023 - 11:41 am ImmuPharma PLC , the specialist... | April 12, 2023